Toyota|$17.53 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$20.97 (¥3,383)+1.26%▲ (in JPY terms)
SoftBank|$40.75 (¥6,574)+3.30%▲ (in JPY terms)
MUFG|$22.31 (¥3,600)+1.67%▲ (in JPY terms)
Keyence|$467.28 (¥75,390)-1.71%▼ (in JPY terms)
Nintendo|$43.70 (¥7,050)-0.79%▼ (in JPY terms)
NTT|$0.93 (¥150)+0.74%▲ (in JPY terms)
Takeda|$33.02 (¥5,327)+0.17%▲ (in JPY terms)
Tokyo Electron|$440.88 (¥71,130)-0.24%▼ (in JPY terms)
Recruit|$78.47 (¥12,660)+2.51%▲ (in JPY terms)
ITOCHU|$11.80 (¥1,904)+1.41%▲ (in JPY terms)
Honda|$9.38 (¥1,514)+1.24%▲ (in JPY terms)
Shin-Etsu|$46.31 (¥7,471)+1.78%▲ (in JPY terms)
Tokio Marine|$47.85 (¥7,720)+1.41%▲ (in JPY terms)
Fast Retailing|$494.55 (¥79,790)-1.77%▼ (in JPY terms)
Toyota|$17.53 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$20.97 (¥3,383)+1.26%▲ (in JPY terms)
SoftBank|$40.75 (¥6,574)+3.30%▲ (in JPY terms)
MUFG|$22.31 (¥3,600)+1.67%▲ (in JPY terms)
Keyence|$467.28 (¥75,390)-1.71%▼ (in JPY terms)
Nintendo|$43.70 (¥7,050)-0.79%▼ (in JPY terms)
NTT|$0.93 (¥150)+0.74%▲ (in JPY terms)
Takeda|$33.02 (¥5,327)+0.17%▲ (in JPY terms)
Tokyo Electron|$440.88 (¥71,130)-0.24%▼ (in JPY terms)
Recruit|$78.47 (¥12,660)+2.51%▲ (in JPY terms)
ITOCHU|$11.80 (¥1,904)+1.41%▲ (in JPY terms)
Honda|$9.38 (¥1,514)+1.24%▲ (in JPY terms)
Shin-Etsu|$46.31 (¥7,471)+1.78%▲ (in JPY terms)
Tokio Marine|$47.85 (¥7,720)+1.41%▲ (in JPY terms)
Fast Retailing|$494.55 (¥79,790)-1.77%▼ (in JPY terms)

2026-07-14 Eisai Co.,Ltd. “New findings on Etalanetug (E2814) will be presented at AAIC 2026 – Etalanetug reduces eMTBR-tau243, a blood biomarker specific to tau aggregates in Alzheimer's disease – Measuring the blood biomarker eMTBR-tau243 may be a practical and minimally invasive method for capturing pathological changes specific to Alzheimer's disease, and is expected to play an important role in the future clinical development of etalanetug.”

2026-07-14 Eisai Co.,Ltd. “New findings on Etalanetug (E2814) will be presented at AAIC 2026 – Etalanetug reduces eMTBR-tau243, a blood biomarker specific to tau aggregates in Alzheimer's disease – Measuring the blood biomarker eMTBR-tau243 may be a practical and minimally invasive method for capturing pathological changes specific to Alzheimer's disease, and is expected to play an important role in the future clinical development of etalanetug.”

コメントする